SRX

0.00%

18.0¢ sierra rutile holdings limited

Ann: Trading Halt, page-77

First 77 Last

Share
Profile

Follow
whytee

16,945 Posts.

2409

23/04/17

12:39

Post #: 24217905
Share

Originally posted by Southoz ↑

I have maybe a slightly different take Tran777.

The way I look at ITT and PP is the difference between efficacy and effectiveness.

I have a new drug. It tastes terrible. I run a trial.

Of the subjects that take the drug as they were supposed to (PP) they do very well. Trouble is many patients don’t take the drug as required and so don’t improve. Consequently the ITT analysis fails.

If the development process is at an early stage this might be a great result. The drug has efficacy and I can fix the taste to improve compliance and hence effectiveness later.

The interaction with ITT and PP with non-inferiority trials however is more subtle.

The first simple point is a failed superiority trial cant become a successful non-inferiority trial. Pretty well full stop at that point.

But secondly PP comparisons (and not ITT) analyses are used in non-inferiority trials because essentially you are reversing the bias.

Imagine you ran a hopeless non-inferiority trial and large numbers of patients in both groups didn’t even start or comply with their treatments. The more hopeless your study was the better for showing non-inferiority (no difference) between the two treatments.

For this reason you take the PP treatment groups and compare the (hopefully) overlapping margins on them. In my hopeless study example I will fail because my small Ns of those who actually complied will produce a large CI.

Here the situation is a little bit trickier between ITT and PP because it would be expected that subject compliance isn’t the issue rather it is patient switching out of treatments. And this is informative of outcome – patients switched because they weren’t doing well. This is the bug bear of oncology trials; the ethics of the life and death make things more complicated.

Expand

Indeed. I'm hopeful that SIRveNIB and FOXFIRE will provide sufficient evidence that patients can be better selected for a particular treatment based on the likelihood of success with that treatment.

This trial, like Sirflox, was designed to fail the primary end point.

SRX Price at posting: $17.00 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

ENV

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

ASN

Utah authorities sign off on Anson's lithium extraction plans at Green River

VUL

Vulcan appoints investment bank and M&A veteran to board

MLS

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

NAM

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

AZY

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

MKG

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

MM8

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

There are more pages in this discussion • 4 more messages in this thread...

First 77 Last

Add SRX (ASX) to my watchlist

(20min delay)
Last 18.0¢		Change 0.000(0.00%)		Mkt cap ! $77.74M

Open	High	Low	Value	Volume
18.0¢	18.0¢	18.0¢	$10.1K	56.10K

Buyers (Bids)

No.	Vol.	Price($)
1	36209025	18.0¢

Sellers (Offers)

Price($)	Vol.	No.
18.5¢	4384259	22

View Market Depth

No.	Vol.	Price($)
1	36209025	0.180
5	3340000	0.175
1	164705	0.170
1	18187	0.165
1	2577	0.097

Price($)	Vol.	No.
0.185	4168658	21
0.190	287869	6
0.195	35000	2
0.200	4000	1
0.205	1000	1

Last trade - 15.18pm 13/09/2024 (20 minute delay)

SRX (ASX) Chart

Ann: Trading Halt, page-77

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Utah authorities sign off on Anson's lithium extraction plans at Green River

Vulcan appoints investment bank and M&A veteran to board

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Trading Halt, page-77

Top Stories

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Utah authorities sign off on Anson's lithium extraction plans at Green River

Vulcan appoints investment bank and M&A veteran to board

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News